viewNemaura Medical Inc

Nemaura taps senior healthcare executive to support global launch of SugarBEAT

Chris Avery has launched numerous glucose monitoring devices, stents and insulin pumps into the UK and European markets

The England-based medtech company will first launch sugarBEAT in the UK, followed by the rest of Europe starting with Germany next quarter

Nemaura Medical Inc (NASDAQ:NMRD) is welcoming a senior healthcare executive to help launch its glucose monitor product to a global audience.

The Loughborough, UK-based medical technology company announced Thursday that Chris Avery is joining the executive team as vice president of global business operations.

Avery will support the worldwide commercial launch of SugarBEAT, the world's first non-invasive continuous glucose monitor (CGM) for people with diabetes.

READ: Nemaura Medical submits De Novo application for SugarBEAT glucose monitor to FDA

As a cofounder of UK medical device distribution company DiagnoSys Medical, Avery oversaw operations and sales, leading the negotiations for the company’s sale to Home Diagnostics and transitioning as the company’s European director.

He has launched numerous glucose monitoring portfolio, stents and insulin pumps into the UK and European markets at Home Diagnostics and Nipro Diagnostics.

Avery was also involved in the pre-launch phase for the distribution of SugarBEAT.

“We are pleased to welcome Chris to the senior management team at Nemaura, as he brings extensive knowledge of SugarBEAT and a proven track record within the diabetes space,” said Dr Faz Chowdhury, Nemaura’s CEO.

“In addition, to overseeing our collaboration with DBE in Europe, we look forward to Chris’ increased involvement in overseeing our global rollout through licensees and global distributors given his sector expertise and extensive relationships,” Chowdhury said in a statement.

READ: Ascendiant Capital Markets initiates coverage of Nemaura Medical with Buy rating, $3.25 price target

Avery will also be involved in the launch of Nemaura’s digital services, according to Chowdhury.

Nemaura recently submitted a De Novo medical device application to the US Food & Drug Administration for approval of SugarBEAT.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Nemaura Medical Inc

Price: 7.7 USD

Market: NASDAQ
Market Cap: $161.41 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Nemaura Medical Inc named herein, including the promotion by the Company of Nemaura Medical Inc in any Content on the Site, the Company...


2 min read